214759-74-7

Usage

Uses

Used in Pharmaceutical Industry:
4-Morpholinobenzylamine is used as a building block for the synthesis of various pharmaceuticals, contributing to the development of new drugs and therapeutic agents.
Used in Agrochemical Industry:
4-MORPHOLINOBENZYLAMINE is utilized as a key intermediate in the production of agrochemicals, aiding in the creation of effective crop protection products.
Used in Dye Production:
4-Morpholinobenzylamine is used as an intermediate in the production of dyes, enhancing the colorfastness and quality of various dye products.
Used in Rubber Chemical Industry:
It serves as an essential component in the synthesis of rubber chemicals, improving the performance and durability of rubber materials.
Used in Surfactant Production:
4-Morpholinobenzylamine is employed as an intermediate in the production of surfactants, which are crucial for the formulation of detergents, cleaners, and other products that require emulsification or dispersion properties.
Used in Therapeutic Applications:
4-Morpholinobenzylamine has been studied for its potential therapeutic applications, particularly in the treatment of neurological disorders, offering a promising avenue for the development of new treatments.
Used in Anti-Cancer Research:
4-MORPHOLINOBENZYLAMINE is also being investigated for its potential as an anti-cancer agent, with research focusing on its ability to target and inhibit cancer cell growth and proliferation.

InChI:InChI=1/C11H16N2O/c12-9-10-1-3-11(4-2-10)13-5-7-14-8-6-13/h1-4H,5-9,12H2

Upstream product

• 10282-31-2 4-morpholinobenzonitrile 
• 183557-77-9 (4-morpholin-4-yl-phenyl)-amide 
• 1194-02-1 4-fluorobenzonitrile 
• 1001242-92-7 2-(4-morpholin-4-ylbenzyl)-1H-isoindole-1,3(2H)-dione 

Downstream Products

• 389602-07-7 N-(4-Morpholin-4-yl-phenylmethyl)-3-(biphenyl-2-carbonyl-amino)-benzoic acid amide 
• 1001242-93-8 methyl 1-[(dimethylamino)sulfonyl]-2-[(4-morpholin-4-ylbenzyl)amino]-5-nitro-1H-benzimidazole-6-carboxylate 
• 1018826-34-0 t-butyl 4-morpholinobenzylcarbamate 
• 1121052-08-1 3-chloro-6-furan-2-yl-8-trifluoromethyl-imidazo[1,2-a]pyridine-2-carboxylic acid 4-morpholin-4-yl-benzylamide 
• 1255097-90-5 C₁₇H₁₈BrN₅O 
• 1416337-23-9 (5-bromo-2-nitrophenyl){[4-(4-morpholinyl)phenyl]methyl}amine 
• 1416337-24-0 (2-amino-5-bromophenyl){[4-(4-morpholinyl)phenyl]methyl}amine 
• 1416337-25-1 6-bromo-1-{[4-(4-morpholinyl)phenyl]methyl}-1H-benzimidazol-2-amine 
• 1416335-35-7 N-[5-(2-amino-1-{[4-(4-morpholinyl)phenyl]methyl}-1H-benzimidazol-6-yl)-2-(methyloxy)-3-pyridinyl]-2,4-difluorobenzenesulfonamide 
• 1429297-45-9 C₂₆H₂₆Cl₂FN₃O₄ 
• 1601403-31-9 N-(4-morpholinobenzyl)-3-oxobenzo[d]isothiazole-2(3H)-carboxamide 

Relevant academic research and scientific papers

Identification of N-Benzyl 3,5-Dinitrobenzamides Derived from PBTZ169 as Antitubercular Agents

A series of benzamide scaffolds were designed and synthesized by the thiazinone ring opening of PBTZ169, and N-benzyl 3,5-dinitrobenzamides were finally identified as anti-TB agents in this work. 3,5-Dinitrobenzamides D5, 6, 7, and 12 exhibit excellent in vitro activity against the drug susceptive Mycobacterium tuberculosis H37Rv strain (MIC: 0.0625 μg/mL) and two clinically isolated multidrug-resistant strains (MIC 0.016-0.125 μg/mL). Compound D6 displays acceptable safety and better pharmacokinetic profiles than PBTZ169, suggesting its promising potential to be a lead compound for future antitubercular drug discovery.

Compounds and methods for inhibiting phosphate transport

Compounds having activity as phosphate transport inhibitors, more specifically, inhibitors of intestinal apical membrane Na/phosphate co-transport, are disclosed. The compounds have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein X, Y, A, R1 and R2 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

Anti-Inflammation Compounds

The present invention refers to: a compound having the general formula (I), wherein n is 0, 1, 2 or; m is 0, 1, 2 or 3; o is 0, 1, 2 or 3; W, X, Y and Z are independently selected from CH, N or N-oxide; A is NR4, C═O, C═S, OP(O)(O), P═O, CH2, or a heteroarly selected from the group consisting of (a), (b), (c), (d), (e), (f), (g); V is C═O, O, S, CH2, or NR5; as well as its use in treating inflammatory diseases such as asthma, COPD, inflammation post infection, arthritis, atherosclerosis, pain and dermatitis.

THERAPEUTIC MACROLIDE COMPOUNDS AND THEIR USE

The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain macrolide compounds (for convenience, collectively referred to herein as "MC compounds"), which, inter alia, are useful in treatment of cancer. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to treat proliferative conditions such as cancer, and in the treatment of diseases and conditions that are mediated by the regulation (e.g. inhibition) of cell proliferation, optionally in combination with another agent.

SUBSTITUTED SULFONAMIDE COMPOUNDS

Substituted sulfonamide derivatives, a process for their preparation, pharmaceutical compositions containing these compounds, and to the use of substituted sulfonamide derivatives in the treatment or inhibition of pain and/or various disorders or disease states.

Potent inhibitors of tRNA-guanine transglycosylase, an enzyme linked to the pathogenicity of the Shigella bacterium: Charge-assisted hydrogen bonding

Improving inhibition: tRNA-Guanine transglycosylase (TGT) is a newly recognized target to reduce the pathogenicity of disease-causing Shigella bacteria. A potent family of inhibitors of this enzyme has been developed by structure-based design. Crystallographic data and pKa, analysis suggest that the aminoimidazole moiety of the central lin-benzoguanine scaffold is protonated and stabilization of the complexes results from charge-assisted hydrogen bonding. (Figure Presented).

In vitro structure-activity relationship and in vivo characterization of 1-(aryl)-3-(4-(amino)benzyl)urea transient receptor potential vanilloid 1 antagonists

The synthesis and structure-activity relationship of 1-(aryl)-3-(4-(amino) benzyl)urea transient receptor potential vanilloid 1 (TRPV1) antagonists are described. A variety of cyclic amine substituents are well tolerated at the 4-position of the benzyl group on compounds containing either an isoquinoline or indazole heterocyclic core. These compounds are potent antagonists of capsaicin activation of the TRPV1 receptor in vitro. Analogues, such as compound 45, have been identified that have good in vivo activity in animal models of pain. Further optimization of 45 resulted in compound 58 with substantially improved microsome stability and oral bioavailability, as well as in vivo activity.

Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor

Compounds of formula (I) are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity, wherein X1, X2, X3, X4, X5, R5, R6, R7, R8a, R8b, R9, Z1, Z2 and L are as defined in the description.

Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor

Compounds of formula (I) are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity.

Synthesis and evaluation of cyclic secondary amine substituted phenyl and benzyl nitrofuranyl amides as novel antituberculosis agents

In an ongoing effort to develop new and potent antituberculosis agents, a second-generation series of nitrofuranyl amides was synthesized on the basis of the lead compound 5-nitrofuran-2-carboxylic acid 3,4-dimethoxybenzylamide. The primary design consideration was to improve the solubility and consequently the bioavailability of the series by the addition of hydrophilic rings to the benzyl and phenyl B ring core. The synthesis of 27 cyclic, secondary amine substituted phenyl and benzyl nitrofuranyl amides is described and their activity against Mycobacterium tuberculosis reported. The series showed a strong structure-activity relationship as the benzyl nitrofuranyl amides were significantly more active than similarly substituted phenyl nitrofuranyl amides. Para-substituted benzyl piperazines showed the most antituberculosis activity. Compounds in the series were subsequently selected for bioavailability and in vivo testing. This study led to the successful discovery of novel compounds with increased antituberculosis activity in vitro and a better understanding of the requisite pharmacological properties to advance this class.